Bill Detail
H.R. 2821
Congress: 119
Title
FDA Modernization Act 3.0
Summary
FDA Modernization Act 3.0 This bill requires the Food and Drug Administration (FDA) to publish an interim final rule implementing a provision of the Consolidated Appropriations Act of 2023 that authorized the use of certain alternatives to animal testing to support investigational use of a new drug. The rule must replace references to animal tests, data, studies, models, and research with references to nonclinical tests, data, studies, models, and research throughout the FDA’s regulations governing investigational new drug applications. The rule must be published within one year of the bill’s enactment, and must take immediate effect as an interim final rule.
Sponsor
Rep. Earl Carter [R-GA-1]
Status
Received in the Senate.
Status as of Jul 28, 1:09 AM · synced 17d ago
Introduced
2025-04-10
Data source mode: congress-gov
Bill Engagement
FDA Modernization Act 3.0 This bill requires the Food and Drug Administration (FDA) to publish an interim final rule implementing a provision of the Consolidated Appropriations…
Lobbyists on the case
- Pharmaceutical Research and Manufacturers of America1 filing · 23 lobs
Prepared intelligence brief
Put this record in the joined picture.
Unlock every organization and lobbyist filing on this bill, the complete event and issue map, private team positions, and recurring movement alerts across the portfolio.